First, we found that OSU13-treated tumor cells activated a proimmunogenic transcriptional program that translated to increased secretion of chemokines CCL5 and CXCL10, which are known to recruit activated T cells and other immune effectors to the sites of inflammation (39). The gene discussed is CCL5; the disease is neoplasm.